MANGOCEUTICALS, INC.
For the period ended Dec 31, 2025. Filed Apr 1, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Apr 1, 2026
MGRX$0.20+1.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, 2025 | December 31, 2024 | |
|---|---|---|
| CURRENT ASSETS | ||
| Cash and cash equivalents | $1,486,338 | $58,653 |
| Prepaid expenses | 7,021 | - |
| Prepaid expenses - related party | 120 | - |
| Deposits | 33,899 | 16,942 |
| Due from related party | 20,056 | - |
| TOTAL CURRENT ASSETS | 1,547,434 | 75,595 |
| NON-CURRENT ASSETS | ||
| Property and equipment, net of accumulated depreciation of $1,012 and $2,256 | 1,794 | 2,806 |
| Right of use - asset | 307,861 | 59,493 |
| Intangible assets - acquired patents and license, net of amortization and impairment | 14,232,484 | 15,232,617 |
| TOTAL NON-CURRENT ASSETS | 14,542,139 | 15,294,916 |
| TOTAL ASSETS | $16,089,573 | $15,370,511 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES | ||
| Accounts payable and accrued liabilities | 416,682 | 837,501 |
| Payroll tax liabilities | 9,421 | - |
| Notes payable | - | 150,000 |
| Right-of-use liability - operating lease | 307,823 | 64,962 |
| Other liabilities - patent purchase payable | 156,642 | 373,000 |
| TOTAL CURRENT LIABILITIES | 890,568 | 1,425,463 |
| TOTAL LIABILITIES | 890,568 | 1,425,463 |
| COMMITMENTS AND CONTINGENCIES (SEE NOTE 11) | ||
| STOCKHOLDERS’ EQUITY | ||
| Series B Convertible Preferred stock, (par value $0.0001), 6,000 shares authorized, 50 and 2,770 shares were issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | - | - |
| Series C Convertible Preferred stock, (par value $0.0001), 6,250,000 shares authorized, 980,000 and 980,000 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 98 | 98 |
| Common stock (par value $0.0001), 200,000,000 shares authorized, of which 15,888,795 and 3,245,641 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 1,589 | 325 |
| Stock warrants | 324,288 | 324,288 |
| Subscription receivable | - | (1,150,000) |
| Additional paid in capital | 55,524,812 | 34,785,749 |
| Accumulated deficit | (40,647,480) | (20,004,486) |
| Accumulated other comprehensive loss | (2,760) | (9,845) |
| TOTAL STOCKHOLDERS’ EQUITY | 15,200,547 | 13,946,129 |
| Non-controlling interest | (1,542) | (1,081) |
| TOTAL STOCKHOLDERS’ EQUITY | 15,199,005 | 13,945,048 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $16,089,573 | $15,370,511 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.